Study of Hospitalised Patients With Acute Respiratory Conditions

Asthma Clinical Trial

— CHESTY  

Official title:

Observational Cohort Study of Hospitalised Patients With Acute Respiratory Conditions

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05095090
• Other study ID #: 0822
• Status: Active, not recruiting
• Start date: February 2, 2022
• Est. completion date: April 30, 2024

Study information

• Verified date: May 2023
• Source: University of Leicester
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study aim to characterise patients admitted to hospital with an acute respiratory condition, or acute worsening of their chronic lung condition. This will enable identification of predictors of future risk, as well as develop potential interventions targets.

Description:

This will be an observational cohort study, recruiting patients who have been admitted to hospital with an acute respiratory condition. This can include exacerbation of an existing chronic lung disease such as asthma, COPD, interstitial lung disease, bronchiectasis and pleural disease, or contracting an acute illness including pulmonary embolism, pneumonia, or any other respiratory infection. The patients will be screened and recruited whilst still hospitalised and followed up for one year after discharge. The participants will undergo a baseline study visit while in hospital, with the option to have further follow up visits (up to three occasions) in the following year to assess clinical recovery. The participants will be offered the choice to undertake the follow up assessments via any of the following routes: - a telephone consultation or - a face to face visit either in the Biomedical Research Centre (BRC) or - during a research visit from another ethically approved study or - during routine clinical follow up organised by the hospital clinical team. The participants can choose not to attend any further follow up visits after discharge. Any planned clinical follow-up arranged by the hospital team will occur according to clinical needs. If the participant is re-admitted during the 12 months after enrolment, assessments identical to the baseline visit can be repeated. A final remote visit will be carried out at 12 months post-discharge (+/- 1 month) to collect data about health care utilisation (e.g. hospitalisation rate, length of stay in hospital, death rate, antibiotic/steroid prescriptions) from both primary and secondary healthcare records. The participants are not required to attend this final visit as data will be collected remotely.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 130
• Est. completion date: April 30, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Hospitalised Patients

Inclusion Criteria:

1. Hospital admission with an acute respiratory diagnosis

2. Participant is willing & able to give informed consent for participation in the study

3. Aged 18 years or above

4. Able (in the Investigators opinion) & willing to comply with all study requirements

Exclusion Criteria:

1. Unstable or life-threatening cardiac disease including myocardial infarction or unstable angina during current admission.

2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

3. Known pregnancy Matched Controls

Inclusion Criteria:

1. Aged 18 years or above

2. Patients with stable chronic respiratory conditions or healthy volunteers

3. Able (in the Investigators opinion) & willing to comply with all study requirements

7.3.2 Exclusion Criteria:

1. Hospitalised due to an acute respiratory illness in the last 6 weeks prior to consent

2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

3. Known pregnancy

Related Conditions & MeSH terms

• Acute Respiratory Disease
• Asthma
• COPD Exacerbation Acute
• Pneumonia
• Respiration Disorders
• Respiratory Tract Diseases

Locations

Country	Name	City	State
United Kingdom	Glenfield Hospital	Leicester

Sponsors (2)

Lead Sponsor	Collaborator
University of Leicester	University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of breathlessness using eMRC dyspnoea scale	To evaluate the degree of breathlessness at baseline and following recovery from acute respiratory illness using Extended MRC dyspnoea scale(eMRC). eMRC dyspnoea scale ranges from 1 to 5b with higher score indicates worse outcomes.	52 weeks
Other	Assessment of quality of Life/symptoms using St. George's Respiratory Questionnaire (SGRQ)	St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.	52 weeks
Primary	30 days hospital re-admission rate	To calculate the percentage of readmission due to the same acute respiratory illness within 30 days from consent	30 days
Primary	Length of index hospital admission stay	To calculate the length of the index hospital stay	Variable (up to 52 weeks)
Primary	30 days mortality rate	To calculate the percentage of mortality within 30 days from consent	30 days
Secondary	Total number of hospital readmission due to same underlying chronic lung disease.	To evaluate the number of hospital readmission episodes due to same underlying chronic lung disease over a 52 weeks period.	52 weeks
Secondary	Total number of non-hospitalised exacerbations of underlying chronic lung disease	To evaluate the number of non-hospitalised exacerbations of chronic lung disease e.g. asthma, Chronic Obstructive Pulmonary Diseases (COPD), etc. over 52 weeks	52 weeks
Secondary	Time from consent to death (respiratory causes and all causes)	To measure the time from consent to death within 52 weeks from consent. This will include both respiratory and all causes of mortality	52 weeks